Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K de Joode

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|February 22, 2021
Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint InhibitionK de Joode, A A M Oostvogels, C H GeurtsvanKessel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2020
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspectiveK de Joode, D W Dumoulin, V Engelen, et al.
ESMO Open|October 20, 2022
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanomaS H A E Derks, K de Joode, E E A P Mulder, et al.
Immuno-Oncology Technology|July 21, 2025
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factorsD C H van Dorst, M M Hofman, R M de Waal, et al.
Scientific Reports|July 3, 2023
The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategiesK de Joode, W S van de Geer, G J L H van Leenders, et al.
BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.
BMC Cancer|March 26, 2021
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trialE E A P Mulder, K de Joode, S Litière, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|February 22, 2021
Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint InhibitionK de Joode, A A M Oostvogels, C H GeurtsvanKessel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2020
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspectiveK de Joode, D W Dumoulin, V Engelen, et al.
ESMO Open|October 20, 2022
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanomaS H A E Derks, K de Joode, E E A P Mulder, et al.
Immuno-Oncology Technology|July 21, 2025
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factorsD C H van Dorst, M M Hofman, R M de Waal, et al.
Scientific Reports|July 3, 2023
The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategiesK de Joode, W S van de Geer, G J L H van Leenders, et al.
BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.
BMC Cancer|March 26, 2021
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trialE E A P Mulder, K de Joode, S Litière, et al.
Pageof 1